BACKGROUND: Liver resection is performed for many types of malignancies. Few reports document actual long-term survival. METHODS: Long-term follow-up of a series of 548 liver resections performed between 1970 and 1992 was performed and is presented. RESULTS: All patients were followed for at least 15 years after surgery. Of the 476 cancer patients, the 5-, 10-, 15-, and 20-year survival rates were 38%, 25%, 20%, and 17%, respectively. Within this group, 108 and 88 patients were actual 10- and 15-year survivors, respectively. Median survival time in months varied by tumor type: metastatic neuroendocrine (81 months), biliary cancer (cholangiocarcinoma) (63 months), gallbladder cancer (47 months), metastatic colorectal cancer (40 months), and hepatocellular carcinoma (27 months). Survivors of each tumor type living more than 25 years were documented. Patients disease-free 10 years after resection for metastatic colorectal cancer or gallbladder cancer were usually considered cured. Patients with diagnoses of hepatocellular carcinoma, cholangiocarcinoma, or other metastases (including neuroendocrine tumors or sarcomas) continued to recur and die of disease. CONCLUSION: Liver resection can be performed with long-term survival and potential curative outcome in a variety of primary and metastatic cancers of the liver.
BACKGROUND: Liver resection is performed for many types of malignancies. Few reports document actual long-term survival. METHODS: Long-term follow-up of a series of 548 liver resections performed between 1970 and 1992 was performed and is presented. RESULTS: All patients were followed for at least 15 years after surgery. Of the 476 cancerpatients, the 5-, 10-, 15-, and 20-year survival rates were 38%, 25%, 20%, and 17%, respectively. Within this group, 108 and 88 patients were actual 10- and 15-year survivors, respectively. Median survival time in months varied by tumor type: metastatic neuroendocrine (81 months), biliary cancer (cholangiocarcinoma) (63 months), gallbladder cancer (47 months), metastatic colorectal cancer (40 months), and hepatocellular carcinoma (27 months). Survivors of each tumor type living more than 25 years were documented. Patients disease-free 10 years after resection for metastatic colorectal cancer or gallbladder cancer were usually considered cured. Patients with diagnoses of hepatocellular carcinoma, cholangiocarcinoma, or other metastases (including neuroendocrine tumors or sarcomas) continued to recur and die of disease. CONCLUSION: Liver resection can be performed with long-term survival and potential curative outcome in a variety of primary and metastatic cancers of the liver.
Authors: Annelise M Gluer; Nicholas Cocco; Jerome M Laurence; Emma S Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson; Vincent W T Lam Journal: HPB (Oxford) Date: 2012-02-28 Impact factor: 3.647
Authors: Benjamin Cahan; Lucille Leong; Lawrence Wagman; David Yamauchi; Stephen Shibata; Sharon Wilzcynski; Lawrence E Williams; Paul Yazaki; David Colcher; Paul Frankel; Anna Wu; Andrew Raubitschek; John Shively; Jeffrey Y C Wong Journal: Cancer Biother Radiopharm Date: 2017-09 Impact factor: 3.099
Authors: Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2011-05-24 Impact factor: 66.675
Authors: Kathleen De Greef; Christian Rolfo; Antonio Russo; Thiery Chapelle; Giuseppe Bronte; Francesco Passiglia; Andreia Coelho; Konstantinos Papadimitriou; Marc Peeters Journal: World J Gastroenterol Date: 2016-08-28 Impact factor: 5.742
Authors: Thiery Chapelle; Bart Op De Beeck; Ivan Huyghe; Sven Francque; Ann Driessen; Geert Roeyen; Dirk Ysebaert; Kathleen De Greef Journal: HPB (Oxford) Date: 2016-03-21 Impact factor: 3.647